Citadel Advisors’s InflaRx IFRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$23.3K Sell
26,037
-36,549
-58% -$34.5K ﹤0.01% 12635
2025
Q4
$63.2K Sell
62,586
-40,365
-39% -$50.1K ﹤0.01% 11920
2025
Q3
$138K Buy
+102,951
New +$109K ﹤0.01% 11598
2025
Q2
Sell
-432,822
Closed -$512K 13682
2025
Q1
$441K Buy
432,822
+381,908
+750% +$720K ﹤0.01% 8749
2024
Q4
$126K Buy
50,914
+27,973
+122% +$53.8K ﹤0.01% 11123
2024
Q3
$35.1K Sell
22,941
-39,484
-63% -$60.1K ﹤0.01% 12284
2024
Q2
$109K Sell
62,425
-35,559
-36% -$52.2K ﹤0.01% 10805
2024
Q1
$151K Buy
97,984
+85,121
+662% +$139K ﹤0.01% 10755
2023
Q4
$21K Sell
12,863
-5
-0% -$9 ﹤0.01% 12584
2023
Q3
$38.3K Buy
+12,868
New +$49K ﹤0.01% 12044
2023
Q2
Sell
-412
Closed -$1.84K 14755
2023
Q1
$799 Sell
412
-9,251
-96% -$20K ﹤0.01% 14413
2022
Q4
$30K Buy
+9,663
New +$24.6K ﹤0.01% 12751
2022
Q2
Sell
-29,363
Closed -$54K 13426
2022
Q1
$54K Sell
29,363
-26,711
-48% -$83.2K ﹤0.01% 12745
2021
Q4
$267K Buy
+56,074
New +$225K ﹤0.01% 11180
2021
Q3
Sell
-10,836
Closed -$28.5K 14194
2021
Q2
$32K Buy
+10,836
New +$35.9K ﹤0.01% 13467
2021
Q1
Sell
-28,271
Closed -$143K 13426
2020
Q4
$143K Buy
+28,271
New +$127K ﹤0.01% 9978
2020
Q2
Sell
-551,274
Closed -$3.58M 10122
2020
Q1
$2.11M Buy
551,274
+445,472
+421% +$1.65M ﹤0.01% 4064
2019
Q4
$419K Buy
105,802
+5,867
+6% +$17.1K ﹤0.01% 7089
2019
Q3
$247K Hold
99,935
﹤0.01% 7858
2019
Q2
$316K Buy
99,935
+4,840
+5% +$153K ﹤0.01% 7508
2019
Q1
$3.59M Buy
95,095
+64,801
+214% +$2.41M ﹤0.01% 3473
2018
Q4
$1.1M Sell
30,294
-49,293
-62% -$1.52M ﹤0.01% 5169
2018
Q3
$2.73M Sell
79,587
-110,593
-58% -$3.57M ﹤0.01% 3876
2018
Q2
$6.13M Buy
190,180
+56,309
+42% +$1.94M ﹤0.01% 2500
2018
Q1
$3.86M Buy
+133,871
New +$3.53M ﹤0.01% 2781

Other funds holding IFRX

Citadel Advisors's IFRX Position: Q1 2026 in Review

Citadel Advisors reduced its InflaRx (IFRX) stake by 58% in Q1 2026, selling an estimated $34.5K and leaving 26,037 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #12635.

Citadel Advisors first reported a position in IFRX in Q1 2018 and has held it in 25 quarters since. The position peaked at $6.13M in Q2 2018. 35 funds tracked by Wall St. Rank hold IFRX as of Q1 2026.

  • Citadel Advisors held 26,037 shares of InflaRx worth $23.3K as of Q1 2026.
  • Citadel Advisors sold 36,549 InflaRx shares in Q1 2026, an estimated $34.5K.
  • InflaRx made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12635 holding.
  • Citadel Advisors first reported a position in InflaRx in Q1 2018 and has held it in 25 quarters since.
  • Citadel Advisors's InflaRx position peaked at $6.13M in Q2 2018.
  • 35 funds tracked by Wall St. Rank held InflaRx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.